Trevi Therapeutics (TRVI) Preferred Dividend Payments (2018 - 2019)
Trevi Therapeutics (TRVI) posted quarterly Preferred Dividend Payments of $686000.0 for Q2 2019, down 46.95% year-over-year from $1.3 million in Q2 2018, and down 55.83% quarter-over-quarter from $1.6 million in Q1 2019.
Powered by 
Analysis
Trevi Therapeutics (TRVI) Preferred Dividend Payments (2018 - 2019) Analysis & Trends
Trevi Therapeutics' Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $686000.0 for Q2 2019.
- In Q2 2019, Preferred Dividend Payments fell 46.95% year-over-year to $686000.0; the TTM figure through Dec 2019 stood at $2.2 million (up 171.97% YoY), while the FY2019 annual figure was $2.2 million, up 705.14% from the prior year.
- Preferred Dividend Payments for Q2 2019 stood at $686000.0, down from $1.6 million in the prior quarter.
- The five-year high for Preferred Dividend Payments was $1.6 million in Q1 2019, with the low at -$4.3 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Trevi Therapeutics | 2.69 Bn | 2.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2019 | -1.33 Mn |
| Mar 31, 2019 | 1.55 Mn |
| Dec 31, 2018 | 1.47 Mn |
| Sep 30, 2018 | 1.36 Mn |
| Jun 30, 2018 | 1.29 Mn |
| Mar 31, 2018 | 1.28 Mn |